Should I buy or sell Editas Medicine stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares. View EDIT analyst ratings or view top-rated stocks .

What is Editas Medicine's stock price target for 2024?

12 analysts have issued 1 year target prices for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they anticipate the company's stock price to reach $13.92 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price. View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts .

How have EDIT shares performed in 2023?

Editas Medicine's stock was trading at $8.87 on January 1st, 2023. Since then, EDIT shares have increased by 23.3% and is now trading at $10.94. View the best growth stocks for 2023 here .

Are investors shorting Editas Medicine?

Editas Medicine saw a drop in short interest in November. As of November 15th, there was short interest totaling 15,870,000 shares, a drop of 5.4% from the October 31st total of 16,770,000 shares. Based on an average daily volume of 1,630,000 shares, the short-interest ratio is currently 9.7 days. View Editas Medicine's Short Interest .

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our EDIT earnings forecast .

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) posted its earnings results on Friday, November, 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.09. The company earned $5.34 million during the quarter, compared to the consensus estimate of $3.70 million. Editas Medicine had a negative trailing twelve-month return on equity of 54.24% and a negative net margin of 792.70%. The company's revenue was up 1171.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.81) earnings per share.

What ETFs hold Editas Medicine's stock?

ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , iShares Genomics Immunology and Healthcare ETF (IDNA) , Horizon Kinetics Medical ETF (MEDX) , Direxion Moonshot Innovators ETF (MOON) , Global X Genomics & Biotechnology ETF (GNOM) and AXS Green Alpha ETF (NXTE) . WisdomTree BioRevolution Fund (WDNA) and

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP) , NVIDIA (NVDA) , Micron Technology (MU) , Intellia Therapeutics (NTLA) , Block (SQ) , Advanced Micro Devices (AMD) , Alibaba Group (BABA) , QUALCOMM (QCOM) , Cisco Systems (CSCO) and Skyworks Solutions (SWKS) .

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a variety of retail and institutional investors. Top institutional investors include Northern Trust Corp (1.09%), Charles Schwab Investment Management Inc. (0.84%), Rafferty Asset Management LLC (0.69%), Mirae Asset Global Investments Co. Ltd. (0.46%), Bank of New York Mellon Corp (0.38%) and Barclays PLC (0.34%). Insiders that own company stock include Baisong Mei, Bruce Eaton , Charles Albright, Gilmore Neil O'neill, James C Mullen , Lisa Anne Michaels , Mark S Shearman and Michelle Robertson . View institutional ownership trends .

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Editas Medicine Stock Price, News & Analysis (NASDAQ:EDIT)

$10.99

-0.12 (-1.08%)

(As of 02:39 PM ET)

Compare

Today's Range: $10.77
▼
$11.20
50-Day Range: $6.25
▼
$11.11
52-Week Range: $6.08
▼
$11.93

Volume: 1.08 million shs
Average Volume: 1.81 million shs
Market Capitalization: $897.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.92

Editas Medicine MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 27.2% Upside
$13.92 Price Target
Short Interest: Healthy
19.43% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.63
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$1,168 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.40) to ($2.55) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

617th out of 958 stocks

Biotechnology Industry

43rd out of 78 stocks

3.2

Analyst's Opinion

Consensus Rating
Editas Medicine has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $13.92, Editas Medicine has a forecasted upside of 27.2% from its current price of $10.94.
Amount of Analyst Coverage
Editas Medicine has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
19.43% of the outstanding shares of Editas Medicine have been sold short.
Short Interest Ratio / Days to Cover
Editas Medicine has a short interest ratio ("days to cover") of 9.7.
Change versus previous month
Short interest in Editas Medicine has recently decreased by 5.37%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Editas Medicine does not currently pay a dividend.
Dividend Growth
Editas Medicine does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Editas Medicine has received a 71.49% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Editas Medicine is -0.63.

2.4

News and Social Media Coverage

News Sentiment
Editas Medicine has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Editas Medicine this week, compared to 3 articles on an average week.
Search Interest
14 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
15 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 114% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,168.00 in company stock.
Percentage Held by Insiders
Only 2.20% of the stock of Editas Medicine is held by insiders.
Percentage Held by Institutions
76.61% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Editas Medicine are expected to decrease in the coming year, from ($2.40) to ($2.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Editas Medicine is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Editas Medicine is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Editas Medicine has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Editas Medicine Stock (NASDAQ:EDIT)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EDIT Stock News Headlines

December 5, 2023 | americanbankingnews.com

Short Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Decreases By 5.4%

November 29, 2023 | morningstar.com

Editas Medicine Inc EDIT

December 7, 2023 | Edge On The Street (Ad)

The Battery Metal Nobody Told You About

According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."

November 28, 2023 | seekingalpha.com

Editas Medicine, Inc. (EDIT) 6th Annual Evercore ISI HealthCONx Conference (Transcript)

November 27, 2023 | finance.yahoo.com

Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 69%

November 25, 2023 | seekingalpha.com

CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

November 14, 2023 | seekingalpha.com

Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript)

November 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB) and Editas Medicine (EDIT)

December 7, 2023 | Edge On The Street (Ad)

The Battery Metal Nobody Told You About

November 8, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Editas Medicine (EDIT), Corvus Pharmaceuticals (CRVS) and AC Immune SA (ACIU)

November 6, 2023 | markets.businessinsider.com

RBC Capital Keeps Their Hold Rating on Editas Medicine (EDIT)

November 6, 2023 | finance.yahoo.com

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus

November 5, 2023 | finance.yahoo.com

Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript

November 5, 2023 | hk.finance.yahoo.com

Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45.

November 3, 2023 | msn.com

Editas Medicine spikes after Q3 results

November 3, 2023 | marketwatch.com

Editas Medicine Shares Climb 20% on 3Q Revenue Growth, Narrower Loss

November 3, 2023 | msn.com

Editas Medicine beats top and bottom line estimates

November 3, 2023 | finance.yahoo.com

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

November 3, 2023 | finance.yahoo.com

Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ...

November 2, 2023 | markets.businessinsider.com

Editas Medicine is about to announce earnings — here's what Wall Street expects

November 2, 2023 | msn.com

Editas Medicine Q3 2023 Earnings Preview

November 2, 2023 | finance.yahoo.com

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

October 29, 2023 | za.investing.com

Pinterest Primed for Rich Ad Spend; Adobe a Powerhouse: Street Calls of the Week

October 25, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Editas Medicine (EDIT) and Revolution Medicines (RVMD)

October 24, 2023 | msn.com

Citigroup Upgrades Editas Medicine (EDIT)

October 18, 2023 | msn.com

JP Morgan Upgrades Editas Medicine (EDIT)

October 17, 2023 | msn.com

Cantor Fitzgerald Downgrades Editas Medicine (EDIT)

See More Headlines

Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/03/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EDIT
CUSIP: N/A
CIK: 1650664
Web: www.editasmedicine.com
Phone: (617) 401-9000
Fax: N/A
Employees: 226
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.92
High Stock Price Target: $30.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +25.9%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-220,430,000.00
Net Margins: -792.70%
Pretax Margin: -792.70%
Return on Equity: -54.24%
Return on Assets: -38.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.12
Quick Ratio: 6.12

Sales & Book Value

Annual Sales: $19.71 million
Price / Sales: 45.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.25 per share
Price / Book: 2.10

Miscellaneous

Outstanding Shares: 81,670,000
Free Float: 79,877,000
Market Cap: $902.45 million
Optionable: Optionable
Beta: 1.96

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Gilmore O'Neill (Age 59)
President, CEO & Director
Comp: $815.37k
Dr. Bruce E. Eaton Ph.D. (Age 69)
Executive VP, CTO & Chief Business Officer
Comp: $786.23k
Dr. Baisong Mei M.D.
Ph.D., Senior VP & Chief Medical Officer
Dr. Feng Zhang Ph.D.
Co-Founder & Scientific Advisory Board Member
Dr. George McDonald Church Ph.D. (Age 69)
Co-Founder & Scientific Advisory Board Member
Dr. J. Keith Joung M.D.
Ph.D., Co-Founder & Scientific Advisory Board Member
Dr. David R. Liu Ph.D.
Co-Founder & Scientific Advisory Board Member
Mr. Erick J. Lucera C.F.A. (Age 55)
CPA, CFO & Executive VP
Mr. Harry R. Gill III (Age 62)
Senior Vice President of Operations
Dr. Linda C. Burkly Ph.D.
Executive VP & Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EDIT Stock Analysis - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings or view top-rated stocks.
What is Editas Medicine's stock price target for 2024?: 12 analysts have issued 1 year target prices for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they anticipate the company's stock price to reach $13.92 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price.
View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts.
How have EDIT shares performed in 2023?: Editas Medicine's stock was trading at $8.87 on January 1st, 2023. Since then, EDIT shares have increased by 23.3% and is now trading at $10.94.
View the best growth stocks for 2023 here.
Are investors shorting Editas Medicine?: Editas Medicine saw a drop in short interest in November. As of November 15th, there was short interest totaling 15,870,000 shares, a drop of 5.4% from the October 31st total of 16,770,000 shares. Based on an average daily volume of 1,630,000 shares, the short-interest ratio is currently 9.7 days.
View Editas Medicine's Short Interest.
When is Editas Medicine's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our EDIT earnings forecast.
How were Editas Medicine's earnings last quarter?: Editas Medicine, Inc. (NASDAQ:EDIT) posted its earnings results on Friday, November, 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.09. The company earned $5.34 million during the quarter, compared to the consensus estimate of $3.70 million. Editas Medicine had a negative trailing twelve-month return on equity of 54.24% and a negative net margin of 792.70%. The company's revenue was up 1171.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.81) earnings per share.

What ETFs hold Editas Medicine's stock?: ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Horizon Kinetics Medical ETF (MEDX), Direxion Moonshot Innovators ETF (MOON), Global X Genomics & Biotechnology ETF (GNOM) and AXS Green Alpha ETF (NXTE).WisdomTree BioRevolution Fund (WDNA) and
What other stocks do shareholders of Editas Medicine own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).
When did Editas Medicine IPO?: (EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Who are Editas Medicine's major shareholders?: Editas Medicine's stock is owned by a variety of retail and institutional investors. Top institutional investors include Northern Trust Corp (1.09%), Charles Schwab Investment Management Inc. (0.84%), Rafferty Asset Management LLC (0.69%), Mirae Asset Global Investments Co. Ltd. (0.46%), Bank of New York Mellon Corp (0.38%) and Barclays PLC (0.34%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Charles Albright, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends.
How do I buy shares of Editas Medicine?: Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EDIT) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial